Editorial Staff

Moving the Needle on Healthcare Cost Containment & Reform

/0 Comments/in , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Today, Pioneer Institute submitted recommendations to the Commonwealth of Massachusetts’ Special Senate Committee on Health Care Cost Containment and Reform. Pioneer applauds provisions of the proposed legislation that would reduce emergency room use and re-admissions, expand scope of practice, and embrace telemedicine. The Committee should also be commended for looking to other states’ accomplishments in this area.

But the current bill raises some concerns. In some instances, we believe it diminishes the potential for greater cost savings by adding unnecessary regulatory burdens. The projected savings relative to 2020 spending are quite modest, at less than 0.2 percent. The Medicaid buy-in program as it is presented is a radical change from the existing program structure – it will require more elaboration and analysis, as it is unclear what the impact of this proposal will be on MassHealth and providers across the Commonwealth. Pioneer also has concerns that the bill could lead to harmful unintended consequences, such as the collapse of the merged private insurance market. We hope the Legislature addresses these issues, but this bill starts an important healthcare cost conversation in Massachusetts, and we commend the Senate for taking the lead in this effort. Read Pioneer’s full letter to the Committee.

Get Updates On Our Healthcare Research and Events!

Related Research

Study Finds Trump’s Most Favored Nation Drug Proposal Could Still Raise Out-of-Pocket Costs Without PBM Reform

BOSTON — Out-of-pocket drug costs for seniors may rise under President Trump’s Most Favored Nation (MFN) proposal if policymakers do not address the role of pharmacy benefit managers (PBMs), according to a brief released today by the Pioneer Institute.

Pioneer Institute Launches Tracker Showing Drug Price Controls Are Raising Out-of-Pocket Costs for Medicare Patients

A new data tool from Pioneer Institute reveals that federal drug price controls—intended to reduce out-of-pocket costs for seniors—are instead making many prescription drugs more expensive for Medicare beneficiaries.  

Pioneer Institute Study Calls for Reforms to Ensure that Pharmacy Benefit Manager Practices Benefit Patients, Healthcare Payers

Congress likely to take up PBM reform early this year; Pioneer Institute Calls for PBM’s to be more transparent

Pioneer Institute: 340B Hospitals Does Not Necessarily Translate to Charity Care

Review of Becker’s List of Health Systems with Strong Finances…

Average Weekly Wages of Healthcare Workers Across a Decade

From 2012-22 the healthcare and social assistance sector has seen the smallest growth in average weekly wages of any large industry in Massachusetts. This potentially has dire consequences on the employment crisis that this industry already faces.

An Evaluation of 340B in Massachusetts

Despite the fact that the 340B Drug Pricing Program has expanded immensely in recent years, the amount of charity care that hospitals are providing has decreased. This points to several problems with the 340B program across the country and in Massachusetts, such as a lack of transparency and inaccessible care.

Do No Harm to the Health Policy Commission

With only weeks left in the Massachusetts legislative calendar,…

New Online Tool Tracks MA Hospital Revenue from Commercial Sources

A new online tool from Pioneer Institute shows a gradual increase in non-commercial (public payer) revenue at Massachusetts hospitals and also reveals a strong relationship between the hospitals with the highest commercial revenue and those with the highest relative prices.

Middlemen Pushing Up Retail Costs of Drugs

The reality is that non-price factors, including several players, are causing net prices to decline and retail prices to increase. Those players include employers, health plans, and pharmacy benefit managers (PBMs), all of whom have continuously circumvented the system through loopholes and complicated systems of reimbursement that tend to hurt patients

Telehealth Progress Slowed in 2023

A new report by Cicero Institute, Pioneer Institute, and Reason Foundation reveals worrying stagnation in state-level telehealth expansion efforts in 2023, with only a few exceptions. Progress made during the pandemic is being lost even as provider shortages worsen, raising concerns about patients’ access to care.

‘High’ U.S. Drug Prices Mask Freeloading by Other Nations

The drug company’s choice is to walk away from millions in revenue from a given country and deny their people a lifesaving drug, or swallow hard and accept an unfair price that is nowhere near the drug’s value. For the sake of shareholders and patients, drug companies typically accept the unfair price and devote the revenue to offsetting their previous investments. In short, other nations are freeloading off of American R&D.

University Science Research Is Under Threat

The Biden administration's formation of a working group to “develop a framework for the implementation of the march-in provision of the Bayh-Dole Act" could have serious adverse consequences for university research and biopharmaceutical innovation. It represents a particularly dangerous threat to the thriving life sciences cluster in Greater Boston.

Opinion: Legislature should act on bill to limit out-of-pocket drug costs

S. 609, a bill that would limit out-of-pocket costs for patients paying for prescription drugs, is a clear step in the right direction. Massachusetts should join 16 other states that have passed similar bills to protect patients.

Healthcare: Suffolk County’s Biggest Driver for Labor and Employment

Suffolk County employment and labor trends have seen steady growth over the past 15 years. The rise of establishments and employment in the health care sector has directly contributed to these trends. Suffolk County has now surpassed Worcester and Essex counties in labor force and employment numbers.

Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.

Drug patents are one of the most important public policy innovations in all of human history, and a boon to patients awaiting cures. Inventions only come when inventors are rewarded, not punished. Patents are not a “necessary evil.”

Study: High List Prices and Deep Discounts for Prescription Drugs Hurt Poor and Sick Patients

A new Pioneer Institute study illustrates how the current system of drug pricing and discounts leads to patients with challenging diseases being charged huge out-of-pocket sums to keep other premiums low, effectively imposing financial penalties on the sick to protect the healthy and wealthy.

Massachusetts’ Misguided Middle-Class Health Insurance Subsidy Expansion

A proposal on Beacon Hill to expand insurance subsidies up to 500 percent of the federal poverty level, could push the small business insurance market into a death spiral, without reducing the number of uninsured and hurting those with preexisting conditions.

Study: Massachusetts Should Join 45 States and Allow Prescribers to Dispense Medications

A Pioneer Institute study shows that middlemen—commercial pharmacies and pharmacy benefit managers—add substantial costs over wholesale prices. Allowing prescribers to dispense routine drugs would save consumers money without compromising safety.